Mifepristone treatment of chronic central serous chorioretinopathy

Retina

Volumn 27, Issue 1, 2007, Pages 119-122

  Nielsen, Jared S ^a   Weinreb, Robert N ^b   Yannuzzi, Lawrence ^c   Jampol, Lee M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EAR AND THROAT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MIFEPRISTONE;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; ARGON LASER; ARTICLE; CASE REPORT; CENTRAL SCOTOMA; CENTRAL SEROUS RETINOPATHY; CLINICAL FEATURE; CLINICAL PROTOCOL; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; OPTICAL COHERENCE TOMOGRAPHY; RETINOPEXY; SUBRETINAL FLUID; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT;

CHOROID DISEASES; CHRONIC DISEASE; EXUDATES AND TRANSUDATES; FLUORESCEIN ANGIOGRAPHY; HORMONE ANTAGONISTS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; MIFEPRISTONE; RETINAL DISEASES; SERUM; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 33846239926     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3180316fd8     Document Type: Article

References (5)

1. Jampol LM, Weinreb R, Yannuzzi L. Involvement of corticosteroids and catecholamines in the pathogenesis of central serous chorioretinopathy: a rationale for new treatment strategies. Ophthalmology 2002;109:1765-1766.
2. Yannuzzi LA, Shakin JL, Fisher YL, Altomonte MA. Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology 1984;91:1554-1572.
3. Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 1994;112:1057-1062.
4. Cadepond F, Ulmann A, Baulieu EE. RU 486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med 1997;48:129-156.
5. Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 2001;86:3568-3573.